Patent 7750127 was granted and assigned to Amgen on July, 2010 by the United States Patent and Trademark Office.
The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.